165 results on '"Whang, Young E."'
Search Results
2. Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report
3. Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer.
4. Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer
5. Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)
6. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
7. BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).
8. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase
9. Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints
10. Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen
11. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
12. c-Abl Is Required for Development and Optimal Cell Proliferation in the Context of p53 Deficiency
13. Evidence for Regulation of the PTEN Tumor Suppressor by a Membrane-Localized Multi-PDZ Domain Containing Scaffold Protein MAGI-2
14. The PTEN/MMAC1 Tumor Suppressor Phosphatase Functions as a Negative Regulator of the Phosphoinositide 3-Kinase/Akt Pathway
15. Inactivation of the Tumor Suppressor PTEN/MMAC1 in Advanced Human Prostate Cancer through Loss of Expression
16. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
17. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
18. Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer
19. Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule
20. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial
21. Activated Cdc42-Associated Kinase Ack1 Promotes Prostate Cancer Progression via Androgen Receptor Tyrosine Phosphorylation
22. Arrays of high-aspect ratio microchannels for high-throughput isolation of circulating tumor cells (CTCs)
23. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps
24. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
25. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer
26. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
27. p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for [Zn.sup.2+]-induced cyclooxygenase-2 expression
28. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway
29. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer
30. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database—UNC GOLD
31. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: Results from Cancer and Leukemia Group B Study 90006
32. The Impact of Altered Annexin I Protein Levels on Apoptosis and Signal Transduction Pathways in Prostate Cancer Cells
33. Involvement of Arginine Methyltransferase CARM1 in Androgen Receptor Function and Prostate Cancer Cell Viability
34. Regulation of Sensitivity to TRAIL by the PTEN Tumor Suppressor
35. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
36. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
37. Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer.
38. ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 (AR-V7) in castrate-resistant prostate cancer
39. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
40. A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
41. A PHASE II STUDY OF ESTRAMUSTINE, DOCETAXEL, AND BEVACIZUMAB IN MEN WITH CASTRATE RESISTANT PROSTATE CANCER: RESULTS OF CANCER AND LEUKEMIA GROUP B (CALGB) 90006
42. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
43. Factors related to men's experience with prostate cancer germline testing.
44. Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding.
45. Intercellular Targets of Prostate Cancer.
46. Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
47. P38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression.
48. Renal cell carcinoma.
49. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway.
50. Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.